Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Second Affiliated Hospital of Air Force Medical University, Xi'an, China
Contact: Study coordinator (Xiaolong Yan) · 47260934@qq.com · 15991269383

Study leads

Xiaolong Yan
Principal Investigator
The Second Affiliated Hospital of Air Force Military Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma · Neoadjuvant Chemoimmunotherapy · Adjuvant Therapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Esophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Xi'an, China